Zydus to present PBC and NASH clinical trial data of Saroglitazar Mg at the AASLD's The Liver Meeting Digital Experience™ 2020

Zydus, a leading discovery based, global pharmaceutical company today announced that a Late-Breaker Oral Presentation and two Poster Presentations on Saroglitazar Mg has been accepted for presentation at The Liver Meeting® 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually from November 13-16, 2020.

Saroglitazar Mg is in various stages of clinical trials to evaluate the safety, tolerability, and efficacy in patients with Primary Biliary Cholangitis (PBC) and Non Alcoholic Steato Hepatitis (NASH).

Speaking on the development, Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said, "We look forward to present the new data on Saroglitazar Mg at The Liver Meeting Digital Experience™, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Zydus is committed to developing novel therapies for patients living with liver diseases like PBC and NASH".

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.417.7 as compared to the previous close of Rs. 411.2. The total number of shares traded during the day was 83357 in over 1767 trades.

The stock hit an intraday high of Rs. 419 and intraday low of 408.8. The net turnover during the day was Rs. 34620070.

Source : Equity Bulls

Keywords